Citadel Advisors
MCRB icon

Citadel Advisors’s Seres Therapeutics MCRB Stock Holding History

Citadel Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,010
Closed -$577K – 13511
2025
Q3 		$577K Buy
30,010
+19,290
+180% +$308K ﹤0.01% 8777
2025
Q2 		$119K Buy
10,720
+10,020
+1,431% +$88.2K ﹤0.01% 11171
2025
Q1 		$9.8K Sell
700
-11,730
-94% -$184K ﹤0.01% 13573
2024
Q4 		$207K Buy
12,430
+2,915
+31% +$47.4K ﹤0.01% 10400
2024
Q3 		$180K Buy
9,515
+4,580
+93% +$92.9K ﹤0.01% 10306
2024
Q2 		$71.4K Buy
4,935
+3,090
+167% +$51.5K ﹤0.01% 11355
2024
Q1 		$28.6K Sell
1,845
-1,855
-50% -$40K ﹤0.01% 12738
2023
Q4 		$104K Buy
3,700
+305
+9% +$8.01K ﹤0.01% 10890
2023
Q3 		$162K Sell
3,395
-3,560
-51% -$272K ﹤0.01% 10239
2023
Q2 		$666K Buy
6,955
+3,645
+110% +$397K ﹤0.01% 7295
2023
Q1 		$375K Buy
3,310
+275
+9% +$29.7K ﹤0.01% 8908
2022
Q4 		$340K Sell
3,035
-195
-6% -$26.1K ﹤0.01% 9042
2022
Q3 		$415K Buy
3,230
+1,925
+148% +$197K ﹤0.01% 8877
2022
Q2 		$90K Sell
1,305
-1,085
-45% -$93.5K ﹤0.01% 11509
2022
Q1 		$340K Sell
2,390
-245
-9% -$37.7K ﹤0.01% 10311
2021
Q4 		$439K Sell
2,635
-165
-6% -$26.2K ﹤0.01% 10003
2021
Q3 		$390K Sell
2,800
-805
-22% -$158K ﹤0.01% 10468
2021
Q2 		$1.72M Buy
3,605
+1,695
+89% +$715K ﹤0.01% 6971
2021
Q1 		$787K Buy
+1,910
New +$879K ﹤0.01% 8684
2020
Q4 		– Sell
-1,440
Closed -$815K – 11265
2020
Q3 		$815K Sell
1,440
-1,870
-56% -$622K ﹤0.01% 6394
2020
Q2 		$315K Buy
+3,310
New +$290K ﹤0.01% 7833
2016
Q4 		– Sell
-695
Closed -$171K – 7603
2016
Q3 		$171K Buy
695
+85
+14% +$29.8K ﹤0.01% 6402
2016
Q2 		$354K Buy
+610
New +$358K ﹤0.01% 4976

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's MCRB Position: Q1 2026 in Review

Citadel Advisors sold out of Seres Therapeutics (MCRB) in Q1 2026, closing a stake of 31,418 shares — an estimated $368K sold.

Citadel Advisors first reported a position in MCRB in Q2 2015 and held it in 35 quarters. The position peaked at $8.02M in Q2 2015. 33 funds tracked by Wall St. Rank hold MCRB as of Q1 2026.

  • Citadel Advisors reported no remaining Seres Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 31,418 Seres Therapeutics shares in Q1 2026, an estimated $368K.
  • Citadel Advisors first reported a position in Seres Therapeutics in Q2 2015 and held it in 35 quarters.
  • Citadel Advisors's Seres Therapeutics position peaked at $8.02M in Q2 2015.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.